ID   WNK3_HUMAN              Reviewed;        1800 AA.
AC   Q9BYP7; B1AKG2; Q5JRC1; Q6JP76; Q8TCX6; Q9HCK6;
DT   02-FEB-2004, integrated into UniProtKB/Swiss-Prot.
DT   19-OCT-2011, sequence version 3.
DT   12-OCT-2022, entry version 184.
DE   RecName: Full=Serine/threonine-protein kinase WNK3 {ECO:0000305};
DE            EC=2.7.11.1 {ECO:0000269|PubMed:17975670};
DE   AltName: Full=Protein kinase lysine-deficient 3 {ECO:0000312|HGNC:HGNC:14543};
DE   AltName: Full=Protein kinase with no lysine 3 {ECO:0000303|PubMed:11571656};
GN   Name=WNK3 {ECO:0000312|HGNC:HGNC:14543};
GN   Synonyms=KIAA1566 {ECO:0000312|EMBL:BAB13392.1}, PRKWNK3
GN   {ECO:0000312|HGNC:HGNC:14543};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000312|EMBL:CAC32455.2};
RN   [1] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), TISSUE SPECIFICITY, AND CHROMOSOMAL
RP   LOCATION.
RC   TISSUE=Brain {ECO:0000269|PubMed:11571656};
RX   PubMed=11571656; DOI=10.1038/sj.onc.1204726;
RA   Verissimo F., Jordan P.;
RT   "WNK kinases, a novel protein kinase subfamily in multi-cellular
RT   organisms.";
RL   Oncogene 20:5562-5569(2001).
RN   [2] {ECO:0000305}
RP   SEQUENCE REVISION TO N-TERMINUS.
RA   Jordan P.;
RL   Submitted (JAN-2002) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=15194194; DOI=10.1016/j.gene.2004.03.009;
RA   Holden S., Cox J., Raymond F.L.;
RT   "Cloning, genomic organization, alternative splicing and expression
RT   analysis of the human gene WNK3 (PRKWNK3).";
RL   Gene 335:109-119(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [5] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 431-1800 (ISOFORM 3).
RC   TISSUE=Brain {ECO:0000269|PubMed:10997877};
RX   PubMed=10997877; DOI=10.1093/dnares/7.4.271;
RA   Nagase T., Kikuno R., Nakayama M., Hirosawa M., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XVIII. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 7:273-281(2000).
RN   [6]
RP   FUNCTION, MUTAGENESIS OF ASP-294, AND TISSUE SPECIFICITY.
RX   PubMed=16275913; DOI=10.1073/pnas.0508303102;
RA   Rinehart J., Kahle K.T., de Los Heros P., Vazquez N., Meade P.,
RA   Wilson F.H., Hebert S.C., Gimenez I., Gamba G., Lifton R.P.;
RT   "WNK3 kinase is a positive regulator of NKCC2 and NCC, renal cation-
RT   Cl- cotransporters required for normal blood pressure homeostasis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:16777-16782(2005).
RN   [7]
RP   FUNCTION.
RX   PubMed=16275911; DOI=10.1073/pnas.0508307102;
RA   Kahle K.T., Rinehart J., de Los Heros P., Louvi A., Meade P., Vazquez N.,
RA   Hebert S.C., Gamba G., Gimenez I., Lifton R.P.;
RT   "WNK3 modulates transport of Cl- in and out of cells: implications for
RT   control of cell volume and neuronal excitability.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:16783-16788(2005).
RN   [8]
RP   FUNCTION.
RX   PubMed=16357011; DOI=10.1113/jphysiol.2005.102202;
RA   Leng Q., Kahle K.T., Rinehart J., MacGregor G.G., Wilson F.H.,
RA   Canessa C.M., Lifton R.P., Hebert S.C.;
RT   "WNK3, a kinase related to genes mutated in hereditary hypertension with
RT   hyperkalaemia, regulates the K+ channel ROMK1 (Kir1.1).";
RL   J. Physiol. (Lond.) 571:275-286(2006).
RN   [9]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=16501604; DOI=10.1038/sj.onc.1209449;
RA   Verissimo F., Silva E., Morris J.D., Pepperkok R., Jordan P.;
RT   "Protein kinase WNK3 increases cell survival in a caspase-3-dependent
RT   pathway.";
RL   Oncogene 25:4172-4182(2006).
RN   [10]
RP   FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH WNK1 AND WNK4, AND ACTIVITY
RP   REGULATION.
RX   PubMed=17975670; DOI=10.1172/jci32033;
RA   Yang C.L., Zhu X., Ellison D.H.;
RT   "The thiazide-sensitive Na-Cl cotransporter is regulated by a WNK kinase
RT   signaling complex.";
RL   J. Clin. Invest. 117:3403-3411(2007).
RN   [11]
RP   FUNCTION.
RX   PubMed=18768590; DOI=10.1152/ajprenal.90229.2008;
RA   Zhang W., Na T., Peng J.B.;
RT   "WNK3 positively regulates epithelial calcium channels TRPV5 and TRPV6 via
RT   a kinase-dependent pathway.";
RL   Am. J. Physiol. 295:F1472-F1484(2008).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [13]
RP   FUNCTION, AND ALTERNATIVE SPLICING.
RX   PubMed=19470686; DOI=10.1681/asn.2008050542;
RA   Glover M., Zuber A.M., O'Shaughnessy K.M.;
RT   "Renal and brain isoforms of WNK3 have opposite effects on NCCT
RT   expression.";
RL   J. Am. Soc. Nephrol. 20:1314-1322(2009).
RN   [14]
RP   FUNCTION.
RX   PubMed=20525693; DOI=10.1074/jbc.m110.103432;
RA   Heise C.J., Xu B.E., Deaton S.L., Cha S.K., Cheng C.J., Earnest S.,
RA   Sengupta S., Juang Y.C., Stippec S., Xu Y., Zhao Y., Huang C.L., Cobb M.H.;
RT   "Serum and glucocorticoid-induced kinase (SGK) 1 and the epithelial sodium
RT   channel are regulated by multiple with no lysine (WNK) family members.";
RL   J. Biol. Chem. 285:25161-25167(2010).
RN   [15]
RP   FUNCTION, ALTERNATIVE SPLICING (ISOFORM 4), AND MUTAGENESIS OF ASP-294.
RX   PubMed=21613606; DOI=10.1152/ajpcell.00070.2011;
RA   Cruz-Rangel S., Melo Z., Vazquez N., Meade P., Bobadilla N.A.,
RA   Pasantes-Morales H., Gamba G., Mercado A.;
RT   "Similar Effects of all WNK3 Variants upon SLC12 Cotransporters.";
RL   Am. J. Physiol. 301:C601-C608(2011).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-62, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [17]
RP   UBIQUITINATION BY KLHL2.
RX   PubMed=23838290; DOI=10.1016/j.bbrc.2013.06.104;
RA   Takahashi D., Mori T., Wakabayashi M., Mori Y., Susa K., Zeniya M.,
RA   Sohara E., Rai T., Sasaki S., Uchida S.;
RT   "KLHL2 interacts with and ubiquitinates WNK kinases.";
RL   Biochem. Biophys. Res. Commun. 437:457-462(2013).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1638, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [19]
RP   VARIANTS [LARGE SCALE ANALYSIS] HIS-704; CYS-854; THR-998; GLU-1169;
RP   ILE-1375; PHE-1533 AND PRO-1634.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine kinase which plays an important role in the
CC       regulation of electrolyte homeostasis, cell signaling, survival and
CC       proliferation. Acts as an activator and inhibitor of sodium-coupled
CC       chloride cotransporters and potassium-coupled chloride cotransporters
CC       respectively (PubMed:16275913, PubMed:16275911, PubMed:16357011).
CC       Phosphorylates WNK4. Regulates the phosphorylation of SLC12A1 and
CC       SLC12A2. Increases Ca(2+) influx mediated by TRPV5 and TRPV6 by
CC       enhancing their membrane expression level via a kinase-dependent
CC       pathway (PubMed:18768590). Inhibits the activity of KCNJ1 by decreasing
CC       its expression at the cell membrane in a non-catalytic manner.
CC       {ECO:0000269|PubMed:16275911, ECO:0000269|PubMed:16275913,
CC       ECO:0000269|PubMed:16357011, ECO:0000269|PubMed:16501604,
CC       ECO:0000269|PubMed:17975670, ECO:0000269|PubMed:18768590,
CC       ECO:0000269|PubMed:20525693}.
CC   -!- FUNCTION: Isoform 1, isoform 2, isoform 3 and isoform 4 stimulate the
CC       activity of SLC12A1, SLC12A2 and SLC12A3 and inhibit the activity of
CC       SLC12A4, SLC12A5, SLC12A6 and SLC12A7. According to PubMed:19470686,
CC       isoform 1 inhibits the activity of SLC12A3.
CC       {ECO:0000269|PubMed:19470686, ECO:0000269|PubMed:21613606}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:17975670};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:17975670};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000250|UniProtKB:Q9H4A3};
CC   -!- ACTIVITY REGULATION: Activation requires autophosphorylation of Ser-
CC       308. Phosphorylation of Ser-304 also promotes increased activity (By
CC       similarity). Kinase activity is inhibited by WNK4.
CC       {ECO:0000250|UniProtKB:Q9JIH7, ECO:0000269|PubMed:17975670}.
CC   -!- SUBUNIT: Interacts with WNK1 and WNK4. {ECO:0000269|PubMed:17975670}.
CC   -!- INTERACTION:
CC       Q9BYP7; P42574: CASP3; NbExp=2; IntAct=EBI-1182602, EBI-524064;
CC       Q9BYP7; P52954: LBX1; NbExp=3; IntAct=EBI-1182602, EBI-20141748;
CC       Q9BYP7; Q04864-2: REL; NbExp=3; IntAct=EBI-1182602, EBI-10829018;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:16501604}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q9BYP7-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9BYP7-2; Sequence=VSP_041933;
CC       Name=3;
CC         IsoId=Q9BYP7-3; Sequence=VSP_041932, VSP_041933;
CC       Name=4;
CC         IsoId=Q9BYP7-4; Sequence=VSP_041932;
CC   -!- TISSUE SPECIFICITY: Expressed in brain, lung, kidney, liver and
CC       pancreas, and in fetal tissues including placenta, fetal brain, lung
CC       and kidney. Very low levels of expression were also detected in fetal
CC       heart, thymus, liver and spleen. Isoform 1 is brain-specific. Isoform 3
CC       is kidney-specific. {ECO:0000269|PubMed:11571656,
CC       ECO:0000269|PubMed:15194194, ECO:0000269|PubMed:16275913}.
CC   -!- PTM: Ubiquitinated by the BCR(KLHL2) complex, leading to its
CC       degradation. {ECO:0000269|PubMed:23838290}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein
CC       kinase family. WNK subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- CAUTION: Was named WNK/'with no lysine(K)' because key residues for
CC       catalysis, including the lysine involved in ATP binding, are either not
CC       conserved or differ compared to the residues described in other kinase
CC       family proteins. {ECO:0000250|UniProtKB:Q9H4A3}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AJ409088; CAC32455.2; -; mRNA.
DR   EMBL; AY082340; AAL99253.1; -; mRNA.
DR   EMBL; AY352048; AAR89465.1; -; mRNA.
DR   EMBL; AL049793; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL591766; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z84469; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AB046786; BAB13392.1; -; mRNA.
DR   CCDS; CCDS14357.1; -. [Q9BYP7-1]
DR   CCDS; CCDS35302.1; -. [Q9BYP7-3]
DR   RefSeq; NP_001002838.1; NM_001002838.3. [Q9BYP7-3]
DR   RefSeq; NP_065973.2; NM_020922.4. [Q9BYP7-1]
DR   RefSeq; XP_006724656.1; XM_006724593.3. [Q9BYP7-3]
DR   RefSeq; XP_011529104.1; XM_011530802.2. [Q9BYP7-4]
DR   RefSeq; XP_016885230.1; XM_017029741.1. [Q9BYP7-1]
DR   RefSeq; XP_016885231.1; XM_017029742.1. [Q9BYP7-1]
DR   RefSeq; XP_016885232.1; XM_017029743.1. [Q9BYP7-1]
DR   RefSeq; XP_016885233.1; XM_017029744.1. [Q9BYP7-1]
DR   RefSeq; XP_016885234.1; XM_017029745.1. [Q9BYP7-2]
DR   PDB; 5NKP; X-ray; 2.80 A; C/D=537-547.
DR   PDB; 5O1V; X-ray; 1.72 A; A/B=132-414.
DR   PDB; 5O21; X-ray; 2.06 A; A/B=132-414.
DR   PDB; 5O23; X-ray; 2.25 A; A/B=132-414.
DR   PDB; 5O26; X-ray; 2.38 A; A/B=133-414.
DR   PDB; 5O2B; X-ray; 2.04 A; A/B=132-414.
DR   PDB; 5O2C; X-ray; 2.40 A; A=123-500.
DR   PDBsum; 5NKP; -.
DR   PDBsum; 5O1V; -.
DR   PDBsum; 5O21; -.
DR   PDBsum; 5O23; -.
DR   PDBsum; 5O26; -.
DR   PDBsum; 5O2B; -.
DR   PDBsum; 5O2C; -.
DR   AlphaFoldDB; Q9BYP7; -.
DR   SMR; Q9BYP7; -.
DR   BioGRID; 122422; 26.
DR   ELM; Q9BYP7; -.
DR   IntAct; Q9BYP7; 34.
DR   STRING; 9606.ENSP00000346667; -.
DR   BindingDB; Q9BYP7; -.
DR   ChEMBL; CHEMBL6055; -.
DR   GuidetoPHARMACOLOGY; 2282; -.
DR   GlyGen; Q9BYP7; 3 sites, 1 O-linked glycan (3 sites).
DR   iPTMnet; Q9BYP7; -.
DR   PhosphoSitePlus; Q9BYP7; -.
DR   BioMuta; WNK3; -.
DR   DMDM; 353526307; -.
DR   EPD; Q9BYP7; -.
DR   jPOST; Q9BYP7; -.
DR   MassIVE; Q9BYP7; -.
DR   MaxQB; Q9BYP7; -.
DR   PaxDb; Q9BYP7; -.
DR   PeptideAtlas; Q9BYP7; -.
DR   PRIDE; Q9BYP7; -.
DR   ProteomicsDB; 79674; -. [Q9BYP7-1]
DR   ProteomicsDB; 79675; -. [Q9BYP7-2]
DR   ProteomicsDB; 79676; -. [Q9BYP7-3]
DR   ProteomicsDB; 79677; -. [Q9BYP7-4]
DR   ABCD; Q9BYP7; 1 sequenced antibody.
DR   Antibodypedia; 26766; 275 antibodies from 28 providers.
DR   DNASU; 65267; -.
DR   Ensembl; ENST00000354646.6; ENSP00000346667.2; ENSG00000196632.11. [Q9BYP7-1]
DR   Ensembl; ENST00000375159.6; ENSP00000364301.2; ENSG00000196632.11. [Q9BYP7-1]
DR   Ensembl; ENST00000375169.7; ENSP00000364312.3; ENSG00000196632.11. [Q9BYP7-3]
DR   GeneID; 65267; -.
DR   KEGG; hsa:65267; -.
DR   UCSC; uc004dtc.3; human. [Q9BYP7-1]
DR   CTD; 65267; -.
DR   DisGeNET; 65267; -.
DR   GeneCards; WNK3; -.
DR   HGNC; HGNC:14543; WNK3.
DR   HPA; ENSG00000196632; Tissue enhanced (epididymis, testis).
DR   MIM; 300358; gene.
DR   neXtProt; NX_Q9BYP7; -.
DR   OpenTargets; ENSG00000196632; -.
DR   PharmGKB; PA33784; -.
DR   VEuPathDB; HostDB:ENSG00000196632; -.
DR   eggNOG; KOG0584; Eukaryota.
DR   GeneTree; ENSGT00940000160145; -.
DR   HOGENOM; CLU_000550_1_2_1; -.
DR   InParanoid; Q9BYP7; -.
DR   OMA; ENNPCQH; -.
DR   OrthoDB; 27514at2759; -.
DR   PhylomeDB; Q9BYP7; -.
DR   TreeFam; TF315363; -.
DR   PathwayCommons; Q9BYP7; -.
DR   Reactome; R-HSA-2672351; Stimuli-sensing channels.
DR   SignaLink; Q9BYP7; -.
DR   SIGNOR; Q9BYP7; -.
DR   BioGRID-ORCS; 65267; 12 hits in 726 CRISPR screens.
DR   ChiTaRS; WNK3; human.
DR   GeneWiki; WNK3; -.
DR   GenomeRNAi; 65267; -.
DR   Pharos; Q9BYP7; Tchem.
DR   PRO; PR:Q9BYP7; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; Q9BYP7; protein.
DR   Bgee; ENSG00000196632; Expressed in corpus epididymis and 140 other tissues.
DR   ExpressionAtlas; Q9BYP7; baseline and differential.
DR   Genevisible; Q9BYP7; HS.
DR   GO; GO:0005912; C:adherens junction; ISS:BHF-UCL.
DR   GO; GO:0005923; C:bicellular tight junction; ISS:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; ISS:UniProtKB.
DR   GO; GO:0019869; F:chloride channel inhibitor activity; IDA:UniProtKB.
DR   GO; GO:0019870; F:potassium channel inhibitor activity; IBA:GO_Central.
DR   GO; GO:0004672; F:protein kinase activity; IDA:BHF-UCL.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0006884; P:cell volume homeostasis; IMP:ARUK-UCL.
DR   GO; GO:0035556; P:intracellular signal transduction; ISS:UniProtKB.
DR   GO; GO:0050801; P:ion homeostasis; IMP:UniProtKB.
DR   GO; GO:0035633; P:maintenance of blood-brain barrier; ISS:ARUK-UCL.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0010766; P:negative regulation of sodium ion transport; IBA:GO_Central.
DR   GO; GO:0007231; P:osmosensory signaling pathway; IMP:ARUK-UCL.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; ISS:ARUK-UCL.
DR   GO; GO:0051928; P:positive regulation of calcium ion transport; IMP:UniProtKB.
DR   GO; GO:0032414; P:positive regulation of ion transmembrane transporter activity; IDA:BHF-UCL.
DR   GO; GO:0010800; P:positive regulation of peptidyl-threonine phosphorylation; IDA:UniProtKB.
DR   GO; GO:1903288; P:positive regulation of potassium ion import across plasma membrane; IBA:GO_Central.
DR   GO; GO:1903078; P:positive regulation of protein localization to plasma membrane; IDA:BHF-UCL.
DR   GO; GO:2000651; P:positive regulation of sodium ion transmembrane transporter activity; IDA:UniProtKB.
DR   GO; GO:0010765; P:positive regulation of sodium ion transport; IDA:BHF-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:BHF-UCL.
DR   GO; GO:0072659; P:protein localization to plasma membrane; IMP:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0090279; P:regulation of calcium ion import; IMP:UniProtKB.
DR   GO; GO:1904062; P:regulation of cation transmembrane transport; IMP:ARUK-UCL.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR024678; Kinase_OSR1/WNK_CCT.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF12202; OSR1_C; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cytoplasm; Kinase;
KW   Nucleotide-binding; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Ubl conjugation.
FT   CHAIN           1..1800
FT                   /note="Serine/threonine-protein kinase WNK3"
FT                   /id="PRO_0000086823"
FT   DOMAIN          147..405
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..25
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          707..739
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          834..868
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          880..912
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1060..1086
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1431..1453
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1465..1496
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1571..1600
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        707..723
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        724..738
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1437..1453
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1466..1492
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        294
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000250|UniProtKB:Q9JIH7"
FT   BINDING         227..230
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:Q9H4A3"
FT   BINDING         277
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:Q9H4A3"
FT   MOD_RES         62
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         304
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:Q9JIH7"
FT   MOD_RES         308
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:Q9JIH7"
FT   MOD_RES         1070
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80XP9"
FT   MOD_RES         1585
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80XP9"
FT   MOD_RES         1638
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   VAR_SEQ         1248..1294
FT                   /note="Missing (in isoform 3 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:10997877,
FT                   ECO:0000303|PubMed:11571656"
FT                   /id="VSP_041932"
FT   VAR_SEQ         1614..1624
FT                   /note="GKSCLINELEN -> D (in isoform 3 and isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10997877,
FT                   ECO:0000303|PubMed:11571656"
FT                   /id="VSP_041933"
FT   VARIANT         704
FT                   /note="Q -> H (in dbSNP:rs56077971)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041323"
FT   VARIANT         854
FT                   /note="S -> C (in a lung squamous cell carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041324"
FT   VARIANT         998
FT                   /note="A -> T (in dbSNP:rs56404148)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041325"
FT   VARIANT         1169
FT                   /note="K -> E (in dbSNP:rs55903619)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041326"
FT   VARIANT         1375
FT                   /note="T -> I (in dbSNP:rs55879434)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041327"
FT   VARIANT         1533
FT                   /note="L -> F (in a lung large cell carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041328"
FT   VARIANT         1634
FT                   /note="S -> P (in a renal clear cell carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041329"
FT   MUTAGEN         294
FT                   /note="D->A: Catalytically inactive form. Inhibits
FT                   sodium-coupled chloride cotransporters and activates
FT                   potassium-coupled chloride cotransporters."
FT                   /evidence="ECO:0000269|PubMed:16275913,
FT                   ECO:0000269|PubMed:21613606"
FT   CONFLICT        10
FT                   /note="S -> N (in Ref. 3; AAL99253)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        431..432
FT                   /note="WV -> RD (in Ref. 5; BAB13392)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1211
FT                   /note="P -> S (in Ref. 5; BAB13392)"
FT                   /evidence="ECO:0000305"
FT   HELIX           132..135
FT                   /evidence="ECO:0007829|PDB:5O2B"
FT   STRAND          138..140
FT                   /evidence="ECO:0007829|PDB:5O1V"
FT   STRAND          146..156
FT                   /evidence="ECO:0007829|PDB:5O1V"
FT   STRAND          159..166
FT                   /evidence="ECO:0007829|PDB:5O1V"
FT   TURN            167..169
FT                   /evidence="ECO:0007829|PDB:5O1V"
FT   STRAND          172..179
FT                   /evidence="ECO:0007829|PDB:5O1V"
FT   HELIX           180..182
FT                   /evidence="ECO:0007829|PDB:5O23"
FT   HELIX           185..200
FT                   /evidence="ECO:0007829|PDB:5O1V"
FT   STRAND          209..215
FT                   /evidence="ECO:0007829|PDB:5O1V"
FT   HELIX           217..219
FT                   /evidence="ECO:0007829|PDB:5O1V"
FT   STRAND          222..228
FT                   /evidence="ECO:0007829|PDB:5O1V"
FT   HELIX           235..239
FT                   /evidence="ECO:0007829|PDB:5O1V"
FT   HELIX           247..265
FT                   /evidence="ECO:0007829|PDB:5O1V"
FT   STRAND          267..269
FT                   /evidence="ECO:0007829|PDB:5O1V"
FT   STRAND          280..283
FT                   /evidence="ECO:0007829|PDB:5O1V"
FT   TURN            285..287
FT                   /evidence="ECO:0007829|PDB:5O1V"
FT   STRAND          290..292
FT                   /evidence="ECO:0007829|PDB:5O1V"
FT   HELIX           297..301
FT                   /evidence="ECO:0007829|PDB:5O1V"
FT   HELIX           304..310
FT                   /evidence="ECO:0007829|PDB:5O21"
FT   HELIX           313..315
FT                   /evidence="ECO:0007829|PDB:5O1V"
FT   HELIX           318..321
FT                   /evidence="ECO:0007829|PDB:5O1V"
FT   HELIX           328..343
FT                   /evidence="ECO:0007829|PDB:5O1V"
FT   TURN            347..350
FT                   /evidence="ECO:0007829|PDB:5O1V"
FT   STRAND          351..353
FT                   /evidence="ECO:0007829|PDB:5O26"
FT   HELIX           354..362
FT                   /evidence="ECO:0007829|PDB:5O1V"
FT   HELIX           368..372
FT                   /evidence="ECO:0007829|PDB:5O1V"
FT   HELIX           376..385
FT                   /evidence="ECO:0007829|PDB:5O1V"
FT   HELIX           390..392
FT                   /evidence="ECO:0007829|PDB:5O1V"
FT   HELIX           396..400
FT                   /evidence="ECO:0007829|PDB:5O1V"
FT   HELIX           403..405
FT                   /evidence="ECO:0007829|PDB:5O1V"
FT   STRAND          408..417
FT                   /evidence="ECO:0007829|PDB:5O2C"
FT   STRAND          424..433
FT                   /evidence="ECO:0007829|PDB:5O2C"
FT   HELIX           435..437
FT                   /evidence="ECO:0007829|PDB:5O2C"
FT   STRAND          438..440
FT                   /evidence="ECO:0007829|PDB:5O2C"
FT   STRAND          447..453
FT                   /evidence="ECO:0007829|PDB:5O2C"
FT   TURN            454..456
FT                   /evidence="ECO:0007829|PDB:5O2C"
FT   HELIX           459..468
FT                   /evidence="ECO:0007829|PDB:5O2C"
FT   HELIX           474..476
FT                   /evidence="ECO:0007829|PDB:5O2C"
FT   HELIX           477..494
FT                   /evidence="ECO:0007829|PDB:5O2C"
FT   HELIX           542..545
FT                   /evidence="ECO:0007829|PDB:5NKP"
SQ   SEQUENCE   1800 AA;  198416 MW;  1766D6AC8C7DE864 CRC64;
     MATDSGDPAS TEDSEKPDGI SFENRVPQVA ATLTVEARLK EKNSTFSASG ETVERKRFFR
     KSVEMTEDDK VAESSPKDER IKAAMNIPRV DKLPSNVLRG GQEVKYEQCS KSTSEISKDC
     FKEKNEKEME EEAEMKAVAT SPSGRFLKFD IELGRGAFKT VYKGLDTETW VEVAWCELQD
     RKLTKAEQQR FKEEAEMLKG LQHPNIVRFY DSWESILKGK KCIVLVTELM TSGTLKTYLK
     RFKVMKPKVL RSWCRQILKG LQFLHTRTPP IIHRDLKCDN IFITGPTGSV KIGDLGLATL
     MRTSFAKSVI GTPEFMAPEM YEEHYDESVD VYAFGMCMLE MATSEYPYSE CQNAAQIYRK
     VTSGIKPASF NKVTDPEVKE IIEGCIRQNK SERLSIRDLL NHAFFAEDTG LRVELAEEDD
     CSNSSLALRL WVEDPKKLKG KHKDNEAIEF SFNLETDTPE EVAYEMVKSG FFHESDSKAV
     AKSIRDRVTP IKKTREKKPA GCLEERRDSQ CKSMGNVFPQ PQNTTLPLAP AQQTGAECEE
     TEVDQHVRQQ LLQRKPQQHC SSVTGDNLSE AGAASVIHSD TSSQPSVAYS SNQTMGSQMV
     SNIPQAEVNV PGQIYSSQQL VGHYQQVSGL QKHSKLTQPQ ILPLVQGQST VLPVHVLGPT
     VVSQPQVSPL TVQKVPQIKP VSQPVGAEQQ AALLKPDLVR SLNQDVATTK ENVSSPDNPS
     GNGKQDRIKQ RRASCPRPEK GTKFQLTVLQ VSTSGDNMVE CQLETHNNKM VTFKFDVDGD
     APEDIADYMV EDNFVLESEK EKFVEELRAI VGQAQEILHV HFATERATGV DSITVDSNSS
     QTGSSEQVQI NSTSTQTSNE SAPQSSPVGR WRFCINQTIR NRETQSPPSL QHSMSAVPGR
     HPLPSPKNTS NKEISRDTLL TIENNPCHRA LFTSKSEHKD VVDGKISECA SVETKQPAIL
     YQVEDNRQIM APVTNSSSYS TTSVRAVPAE CEGLTKQASI FIPVYPCHQT ASQADALMSH
     PGESTQTSGN SLTTLAFDQK PQTLSVQQPA MDAEFISQEG ETTVNTEASS PKTVIPTQTP
     GLEPTTLQPT TVLESDGERP PKLEFADNRI KTLDEKLRNL LYQEHSISSI YPESQKDTQS
     IDSPFSSSAE DTLSCPVTEV IAISHCGIKD SPVQSPNFQQ TGSKLLSNVA ASQPANISVF
     KRDLNVITSV PSELCLHEMS SDASLPGDPE AYPAAVSSGG AIHLQTGGGY FGLSFTCPSL
     KNPISKKSWT RKLKSWAYRL RQSTSFFKRS KVRQVETEEM RSAIAPDPIP LTRESTADTR
     ALNRCKAMSG SFQRGRFQVI TIPQQQSAKM TSFGIEHISV FSETNHSSEE AFIKTAKSQL
     VEIEPATQNP KTSFSYEKLQ ALQETCKENK GVPKQGDNFL SFSAACETDV SSVTPEKEFE
     ETSATGSSMQ SGSELLLKER EILTAGKQPS SDSEFSASLA GSGKSVAKTG PESNQCLPHH
     EEQAYAQTQS SLFYSPSSPM SSDDESEIED EDLKVELQRL REKHIQEVVN LQTQQNKELQ
     ELYERLRSIK DSKTQSTEIP LPPASPRRPR SFKSKLRSRP QSLTHVDNGI VATGKSCLIN
     ELENPLCVES NAASCQQSPA SKKGMFTDDL HKLVDDWTKE AVGNSLIKPS LNQLKQSQHK
     LETENWNKVS ENTPSTMGYT STWISSLSQI RGAVPTSLPQ GLSLPSFPGP LSSYGMPHVC
     QYNAVAGAGY PVQWVGISGT TQQSVVIPAQ SGGPFQPGMN MQAFPTSSVQ NPATIPPGPK
//
